We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
- Authors
Richardson, Paul G; Wolf, Jeff; Jakubowiak, Andrzej; Zonder, Jeff; Lonial, Sagar; Irwin, David; Densmore, John; Krishnan, Amrita; Raje, Noopur; Bar, Michael; Martin, Tom; Schlossman, Robert; Ghobrial, Irene M; Munshi, Nikhil; Laubach, Jacob; Allerton, Jeff; Hideshima, Teru; Colson, Kathleen; Poradosu, Enrique; Gardner, Lesa; Sportelli, Peter; Anderson, Kenneth C
- Abstract
Novel agents have improved patient outcome in relapsed or relapsed/refractory multiple myeloma (MM). Preclinical data show that the novel signal transduction modulator, perifosine, enhances the cytotoxicity of dexamethasone and bortezomib. Clinical data suggest that perifosine in combination with dexamethasone has activity in relapsed or relapsed/refractory MM.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 32, p4243
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.33.9788